Symptomatic vitreomacular adhesion (VMA) or vitreomacular traction can cause anatomical disturbances of the macula and formation of macular hole.^[@R1]--[@R3]^ Reduced visual acuity and visual distortion, such as metamorphopsia, can significantly affect quality of life and is associated with symptomatic VMA.^[@R4]^ The current treatment options for symptomatic VMA, which depend on the disease stage and progression, include watchful waiting, pharmacologic vitreolysis, and pars plana vitrectomy.^[@R2],[@R5]^ Although symptomatic VMA resolves spontaneously in some patients (10%--35% of cases), if left untreated, symptomatic VMA can progress and may lead to vision loss.^[@R3],[@R6],[@R7]^

Ocriplasmin is a recombinant truncated form of human plasmin indicated for treatment of symptomatic VMA,^[@R8],[@R9]^ which acts by hydrolyzing the protein matrix involved in the tractional forces at the macular region.^[@R8]^ Regulatory approvals were based on data from the pivotal Phase 3 Microplasmin for Intravitreous Injection-Traction Release without Surgical Treatment (MIVI-TRUST) ocriplasmin trials (NCT00781859 and NCT00798317) in patients with symptomatic VMA.^[@R3],[@R8]^ The subsequent Phase 3b Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS, NCT01429441) study confirmed the efficacy and safety results of the 6-month MIVI-TRUST trials over 24 months in patients with symptomatic VMA.^[@R10]^

Outcomes from patient self-assessment are needed to understand if the improved clinical outcomes are translating into improved quality of life. The patient\'s functional ability is as important as the clinical measure of VMA resolution. The validated 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) measures patients\' perceptions of vision-related function and of the ways in which treatment affects daily activities related to visual function.^[@R11]--[@R13]^ Here, we present patient-reported outcomes for visual function from the OASIS study using the VFQ-25 questionnaire to evaluate the therapeutic and functional benefit of ocriplasmin versus sham.

Methods {#s1}
=======

Study Design and Patient Population {#s1-1}
-----------------------------------

OASIS (NCT01429441) was a Phase 3b, randomized, multicenter, double-masked, sham-controlled, clinical trial of ocriplasmin in patients with symptomatic VMA, including macular hole. Details of the trial design, patient population, and efficacy and safety outcomes were published previously.^[@R10]^ Briefly, eligible patients had symptomatic VMA with a best-corrected visual acuity score of 20/32 or worse on the Early Treatment Diabetic Retinopathy Study chart in the study eye and 20/800 or better in the nonstudy eye. Patients were randomized (2:1) to receive a single intravitreal injection of ocriplasmin (0.125 mg) or sham. The randomization was stratified by the baseline presence of full-thickness macular hole (FTMH).

The study was conducted according to the Declaration of Helsinki and the International Conference for Harmonisation (ICH) Guideline for Good Clinical Practice. Ethics committee and institutional review board approval was obtained. Written informed consent was obtained from each patient before enrollment.

Assessments {#s1-2}
-----------

Patient-reported visual function was recorded at baseline and at 6, 12, and 24 months after injection using the VFQ-25 questionnaire to measure the vision-targeted health status. The administrator of the VFQ-25 questionnaire was masked to the intervention arm. The VFQ-25 includes a global composite score, a single general health subscale score, and the following 11 vision-related subscale scores: color vision, dependency, distance activities, driving, general vision, mental health, near activities, ocular pain, peripheral vision, role difficulties, and social functioning. Scoring excluded items wherever data were missing and was based on an algorithm for the VFQ-25 questionnaire, in which 0 represents the worst and 100 represents the best possible score.^[@R14]^ Changes (improvement or worsening) of ≥5 points from baseline in VFQ-25 composite and subscale scores were considered clinically meaningful.^[@R15]--[@R17]^ VFQ-25 composite and subscale scores were examined by baseline FTMH (yes/no), symptomatic VMA resolution at Day 28 (yes/no), and vitrectomy while on study (yes/no).

Statistical Analysis {#s1-3}
--------------------

VFQ-25 analyses included all randomized patients who received an injection of ocriplasmin in the study eye and had data for at least one follow-up visit. A ≥5-point improvement in VFQ-25 scores at Month 24 was a predetermined secondary endpoint of the OASIS study.^[@R10]^ The threshold for counting a difference between groups in percentages of patients with a ≥5-point change in composite and subscale scores was calculated as 100% (1/N) where N is the number of patients in the smaller subgroup of the comparison. The study was not specifically powered to detect differences between treatment groups in the percentage of patients with a ≥5-point change in VFQ-25 composite score at Month 24, nor any other subscale scores. When a visit did not take place, the scores of the previous visit were carried forward using the last-observation-carried-forward method. The VFQ-25 results were summarized by treatment and visit using descriptive statistics. When calculated across strata (irrespective of FTMH status at baseline), percentages were computed using the inverse of variance formula. The percentages of patients with at least a 5-point change (increase and decrease) in VFQ-25 scores were compared between ocriplasmin and sham groups for the overall population (irrespective of FTMH status at baseline) using the Cochran--Mantel--Haenszel test. Within strata (stratum defined based on the FTMH status at baseline), the Pearson chi-square test was used. Comparisons of changes in VFQ-25 scores (≥5-point) also were made between ocriplasmin and sham groups based on baseline FTMH status (present, absent), the status of nonsurgical resolution of VMA at Day 28 (yes, no), and vitrectomy while on study (yes, no).

Results {#s2}
=======

Baseline Demographics and Disease Characteristics {#s2-1}
-------------------------------------------------

Of the 220 patients enrolled into the OASIS study, 146 received a single intravitreal ocriplasmin injection, and 74 received a sham injection. Two patients, one from each treatment group, did not attend the postinjection visits and were therefore excluded from this analysis. Demographics and baseline ocular characteristics are presented in Table [1](#T1){ref-type="table"}.

###### 

Demographic and Baseline Ocular Characteristics (Full Analysis Set)\*

![](retina-40-1331-g001)

Patient-Reported Visual Function {#s2-2}
--------------------------------

A larger percentage of patients treated with ocriplasmin than with sham achieved a ≥5-point increase in VFQ-25 composite score from baseline at Month 24 (51.4% vs. 30.1%; difference: 95% confidence interval \[CI\], 8.1--34.5, *P* = 0.003; Figure [1](#F1){ref-type="fig"}). A smaller percentage of patients in the ocriplasmin group versus sham experienced a ≥5-point decrease in the VFQ-25 composite score from baseline at Month 24 (9.5% vs. 15.6%; difference: 95% CI, −15.6 to 3.5, *P* = 0.191; Figure [1](#F1){ref-type="fig"}). For all subscale scores, a larger percentage of patients treated with ocriplasmin versus sham achieved a ≥5-point improvement in subscale scores from baseline at Month 24 (Figure [1](#F1){ref-type="fig"}). Except for color vision, dependency, and social functioning, a smaller percentage of ocriplasmin recipients than of sham recipients had a ≥5-point decrease in subscale scores at Month 24 (Figure [1](#F1){ref-type="fig"}). The Month 6 and 12 results for the VFQ-25 composite and subscale scores followed a similar pattern to the Month 24 data, generally favoring ocriplasmin (see **Figure**, **Supplemental Digital Content 1**, <http://links.lww.com/IAE/B22>, which shows data for patients who had at least a 5-point change in VFQ-25 scores from baseline to Months 6 and 12).

![Patients with at least a 5-point change in VFQ-25 scores from baseline to Month 24 (LOCF, irrespective of vitrectomy). For driving subscale: ocriplasmin (n = 132) and sham (n = 69). \**P* \< 0.01. Error bars represent 95% CIs. The threshold for counting a difference between groups in percentages of patients with a ≥5-point change in composite and subscale scores was calculated as 100% (1/N) where N is the number of patients in the smaller subgroup of the comparison. LOCF, last observation carried forward; VFQ-25, 25-item National Eye Institute Visual Function Questionnaire.](retina-40-1331-g002){#F1}

Patient-Reported Visual Function by Baseline Full-Thickness Macular Hole Status {#s2-3}
-------------------------------------------------------------------------------

At baseline, 34.5% (50/145) of ocriplasmin recipients and 35.6% (26/73) of sham recipients had FTMH. A larger percentage of patients in the ocriplasmin group than sham achieved a ≥5-point improvement from baseline in the VFQ-25 composite score at Month 24 regardless of baseline FTMH status (with FTMH: 60% vs. 26.9% \[95% CI, 11.3--54.9\], *P* = 0.006; without FTMH: 46.3% vs. 31.9% \[95% CI, −2.3 to 31.1\], *P* = 0.101; Figure [2](#F2){ref-type="fig"}). Results for worsening of patient-reported visual function by FTMH status were similar. A smaller proportion of patients in the ocriplasmin group than sham had a ≥5-point decrease in the VFQ-25 composite score at Month 24 regardless of baseline FTMH status (with FTMH: 6.0% vs. 11.5% \[95% CI, −19.5 to 8.4\], *P* = 0.396; without FTMH: 12.6% vs. 19.1% \[95% CI, −19.6 to 6.6\], *P* = 0.303; Figure [2](#F2){ref-type="fig"}). As with the composite scores, the proportions of patients with ≥5-point changes in subscale scores generally favored ocriplasmin over sham. For patients with baseline FTMH, a larger percentage of patients in the ocriplasmin group than sham experienced a ≥5-point improvement in 9 of 12 subscale scores at Month 24. For patients without baseline FTMH, a larger percentage of patients achieved a ≥5-point improvement for 10 of 12 subscale scores with ocriplasmin than sham. The ≥5-point worsening in subscale scores occurred in a smaller proportion of patients with ocriplasmin than sham for most subscale scores regardless of baseline FTMH status. The Month 6 and 12 findings were similar to the results at Month 24 for the FTMH subgroups (see **Figure**, **Supplemental Digital Content 2**, <http://links.lww.com/IAE/B23>, which shows data for patients with a ≥5-point change in VFQ-25 scores from baseline to Months 6 and 12 by FTMH at baseline).

![Patients with at least a 5-point change in VFQ-25 scores from baseline to Month 24 by FTMH at baseline (LOCF, irrespective of vitrectomy). Panel A shows patients with FTMH at baseline, panel B shows patients without FTMH at baseline. For driving subscale: ocriplasmin (n = 46) and sham (n = 25) in subgroup with FTMH at baseline. For driving subscale: ocriplasmin (n = 86) and sham (n = 44) in subgroup without FTMH at baseline. \**P* \< 0.01. Error bars represent 95% CIs. The threshold for counting a difference between groups in percentages of patients with a ≥5-point change in composite and subscale scores was calculated as 100% (1/N) where N is the number of patients in the smaller subgroup of the comparison. FTMH, full-thickness macular hole; LOCF, last observation carried forward; VFQ-25, 25-item National Eye Institute Visual Function Questionnaire.](retina-40-1331-g003){#F2}

Patient-Reported Visual Function by Vitreomacular Adhesion Resolution at Day 28 {#s2-4}
-------------------------------------------------------------------------------

Nonsurgical symptomatic VMA resolution was achieved at Day 28 in 62/145 (41.7%) patients treated with ocriplasmin and 5/73 (6.2%) patients receiving sham (*P* \< 0.001). Regardless of symptomatic VMA resolution at Day 28, a larger percentage of patients in the ocriplasmin group than sham experienced a ≥5-point improvement in VFQ-25 composite score at Month 24 (with VMA resolution: 57.1% vs. 39.8% \[95% CI, −27.0 to 61.6\] *P* = 0.483; without VMA resolution: 48.7% vs. 29.5% \[95% CI, 4.0--34.5\] *P* = 0.019). A smaller percentage of patients without VMA resolution at Day 28 experienced a ≥5-point worsening in the VFQ-25 composite score at Month 24 with ocriplasmin than sham (13.3% vs. 17.1% \[95% CI, −15.2 to 7.7\] *P* = 0.552). The trend was reversed in those with VMA resolution, in whom a larger percentage of ocriplasmin recipients experienced a ≥5-point worsening in the composite score (4.7% vs. 0.0% \[95% CI, −0.6 to 9.9\] *P* = 0.632). However, it should be noted that the subgroup of patients in the sham group with symptomatic VMA resolution was small (n = 5), and results should be interpreted with caution.

In ocriplasmin recipients, a larger percentage of patients with VMA resolution at Day 28 compared with no VMA resolution achieved a ≥5-point improvement in composite and 6 subscale scores at Month 24 (Figure [3](#F3){ref-type="fig"}A \[top panel\]). Except for color vision and peripheral vision subscales, a smaller percentage of patients with VMA resolution in the ocriplasmin group experienced a ≥5-point worsening in composite and subscale scores than patients without VMA resolution. The Month 6 and Month 12 findings were similar to the results at Month 24 for the subgroups defined by symptomatic VMA resolution (see **Table**, **Supplemental Digital Content 3**, <http://links.lww.com/IAE/B24>, which shows a ≥5-point change in VFQ-25 scores from baseline to Month 6 and Month 12 in the ocriplasmin group by VMA resolution at Day 28 and by vitrectomy).

![Patients with at least a 5-point change in VFQ-25 scores from baseline to Month 24 by VMA resolution at Day 28 (panel A) and vitrectomy (panel B). For driving subscale: ocriplasmin with resolution (n = 58) and ocriplasmin without resolution (n = 74). For driving subscale: ocriplasmin with vitrectomy (n = 45) and ocriplasmin without vitrectomy (n = 87). Error bars represent 95% CIs. The threshold for counting a difference between groups in percentages of patients with a ≥5-point change in composite and subscale scores was calculated as 100% (1/N) where N is the number of patients in the smaller subgroup of the comparison. LOCF, last observation carried forward; VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; VMA, vitreomacular adhesion.](retina-40-1331-g004){#F3}

Patient-Reported Visual Function by Vitrectomy Status {#s2-5}
-----------------------------------------------------

Overall 48/145 (33.1%) patients in the ocriplasmin group and 32/73 (43.8%) patients in the sham group underwent vitrectomy. A larger percentage of patients in the ocriplasmin group than sham achieved a ≥5-point improvement in the VFQ-25 composite score at Month 24 regardless of vitrectomy status (with vitrectomy: 58.5% vs. 39.9% \[95% CI, −2.7 to 39.9\] *P* = 0.121; without vitrectomy: 48.0% vs. 16.1% \[95% CI, 17.6--46.2\] *P* = 0.006). Results for worsening of patient-reported visual function by vitrectomy status were similar. A smaller percentage of patients in the ocriplasmin group than sham experienced a ≥5-point worsening in the VFQ-25 composite score at Month 24, regardless of vitrectomy status (with vitrectomy: 8.6% vs. 16.5% \[95% CI, −22.8 to 7.0\] *P* = 0.304; without vitrectomy: 8.3% vs. 6.9% \[95% CI, −7.6 to 10.4\] *P* = 0.523).

In the ocriplasmin group, a larger percentage of patients with vitrectomy than no vitrectomy achieved a ≥5-point improvement in composite and 7 subscale scores at Month 24 (Figure [3](#F3){ref-type="fig"}B). Similar percentages of patients in the ocriplasmin group experienced a ≥5-point worsening in the VFQ-25 composite score at Month 24 regardless of vitrectomy status. A larger percentage of patients with vitrectomy than without vitrectomy in the ocriplasmin group experienced a ≥5-point worsening in distance activities, ocular pain, and peripheral vision subscale scores. The Month 6 and Month 12 findings for the subgroups defined by vitrectomy are presented in **Supplemental Digital Content 3** (see **Table**, <http://links.lww.com/IAE/B24>). In the sham group, a larger percentage of patients with vitrectomy than without experienced a ≥5-point improvement in composite and 10 of 12 subscale scores at Month 24. A greater percentage of patients in the sham group with vitrectomy than without experienced a ≥5-point worsening in composite and 6 subscale scores.

Discussion {#s3}
==========

The Phase 3b OASIS study patient-reported visual function outcomes demonstrate that treatment with a single intravitreal injection of ocriplasmin in patients with symptomatic VMA improved self-reported visual function during 2 years of follow-up. Ocriplasmin recipients also were less likely to report worsening visual functioning compared with patients treated with sham injection. The OASIS patient-reported visual function outcomes are consistent with those reported in the MIVI-TRUST trials, in which the percentage of patients with at least a 5-point improvement in the VFQ-25 composite score at Month 6 was comparable (39.4% OASIS and 36.0% MIVI-TRUST).^[@R18]^ The lower percentages of patients with a ≥5-point worsening in the VFQ-25 composite score at Month 6 also were comparable (11.8% OASIS and 15.0% MIVI-TRUST).^[@R18]^ These findings complement clinical endpoints and can aid in clinical decision-making. Indeed, patient-reported outcomes are powerful tools for validating the effects of a treatment on patient health and daily-life activities, both in terms of benefits and potential adverse effects.

Clinically meaningful improvements in VFQ-25 composite scores favored ocriplasmin over sham regardless of baseline FTMH status or symptomatic VMA resolution at Day 28. Results for ≥5-point improvements at Month 24 in the VFQ-25 subscale scores also generally favored ocriplasmin over sham across the subgroups analyzed. Within the ocriplasmin group, patients with FTMH at baseline had better patient-reported outcomes than those without FTMH at baseline.

As might be expected, larger improvements in patient-reported visual function correlated with VMA resolution at Day 28. In addition, even in those patients with persistent symptomatic VMA, the improvements in the VFQ-25 composite score were larger with ocriplasmin treatment than sham. A similar finding was observed in the MIVI-TRUST trial, in which larger improvements in patient-reported visual function correlated with partial or complete symptomatic VMA resolution, suggesting that partial symptomatic VMA release may be sufficient to reduce traction and improve visual function.^[@R18]^ In addition, recent case studies suggest improved clinical symptoms and visual acuity after ocriplasmin treatment despite achieving only partial symptomatic VMA release at Day 28.^[@R19]^ However, the analysis by symptomatic VMA resolution should be taken with caution because the number of patients in the sham group with symptomatic VMA resolution at Day 28 was small (n = 5).

Clinically meaningful improvements in VFQ-25 composite scores also favored ocriplasmin over sham regardless of vitrectomy. Composite scores were 18.6% higher with vitrectomy and 31.9% higher without vitrectomy in the ocriplasmin group than in the sham group. These improvements were observed despite the fact that patients with vitrectomy had better patient-reported outcomes than those without vitrectomy within the ocriplasmin and sham groups.

The analyses of patient-reported visual function outcomes described here have some limitations. First, the subgroup analyses were descriptive in nature only. Moreover, the symptomatic VMA resolution and vitrectomy subgroups were based on treatment-dependent variables as opposed to a random assignment. Another limitation is that 28% of patients discontinued the study before the conclusion of the 2-year follow-up period, which led to missing values.^[@R10]^ Furthermore, the 2-year time frame of the OASIS study allowed additional confounding factors, such as cataract surgeries and vitrectomies during the study follow-up period. However, the 2-year follow-up period and the randomized, double-masked design of the study suggest that the differences observed are unbiased and causal.

In conclusion, treatment with a single ocriplasmin injection led to clinically meaningful improvements in patient-reported visual function measured by the VFQ-25 questionnaire over 24 months in patients with symptomatic VMA.
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